This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Stanley J. Robboy, MD; W. Dwayne Lawrence, MD
National Collaborative Diethylstilbestrol Adenosis Project Massachusetts General Hospital Boston

Kenneth L. Noller, MD; Peter O'Brien, PhD; Eric Bergstrahl; Susan McGorray; Barbara C. Tilley, PhD
Mayo Clinic Rochester, Minn

Raymond H. Kaufman, MD
Baylor College of Medicine Houston

JAMA. 1986;255(1):37.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.—

Dr Richart asserts that advances in our knowledge about the morphological appearances of HPV could have led to bias in the National Collaborative Diethylstilbestrol Adenosis Project study, in which tissue slides have been analyzed since 1976.¹ Although some bias is possible, we believe it to be minimal since the slides disclosing dysplasia were reviewed by all pathologists and cytologists, and many slides were rereviewed periodically over a period of years as part of quality-control procedures.

A major problem facing all pathologists and cytologists today is in fact the diagnostic criteria distinguishing HPV lesions from dysplasia and carcinoma in situ (collectively, Richart's CIN). Do lesions exhibiting both koilocytosis and marked nuclear atypia represent one disease state or both simultaneously? We have demonstrated that such lesions may have HPV demonstrable by immunoperoxidase stains while also demonstrating aneuploidy by microspectrophotometric analysis of Feulgen-stained slides.² We believe that many lesions . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?